OTC Markets EXMKT - Delayed Quote USD

Basilea Pharmaceutica AG (BPMUF)

Compare
51.26 0.00 (0.00%)
At close: September 23 at 4:00 PM EDT
Loading Chart for BPMUF
DELL
  • Previous Close 0.00
  • Open 44.00
  • Bid --
  • Ask --
  • Day's Range 44.45 - 44.45
  • 52 Week Range 38.60 - 51.26
  • Volume 100
  • Avg. Volume 1
  • Market Cap (intraday) 655.226M
  • Beta (5Y Monthly) 0.70
  • PE Ratio (TTM) --
  • EPS (TTM) -0.08
  • Earnings Date Aug 13, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

www.basilea.com

156

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BPMUF

View More

Performance Overview: BPMUF

Trailing total returns as of 9/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BPMUF
25.02%
MSCI WORLD
16.55%

1-Year Return

BPMUF
2.52%
MSCI WORLD
28.26%

3-Year Return

BPMUF
11.43%
MSCI WORLD
18.91%

5-Year Return

BPMUF
14.39%
MSCI WORLD
68.38%

Compare To: BPMUF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BPMUF

View More

Valuation Measures

Annual
As of 9/23/2024
  • Market Cap

    655.23M

  • Enterprise Value

    713.38M

  • Trailing P/E

    50.35

  • Forward P/E

    15.43

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.55

  • Price/Book (mrq)

    31.44

  • Enterprise Value/Revenue

    4.07

  • Enterprise Value/EBITDA

    24.28

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.44%

  • Return on Assets (ttm)

    -2.05%

  • Return on Equity (ttm)

    -4.10%

  • Revenue (ttm)

    149.02M

  • Net Income Avi to Common (ttm)

    -652k

  • Diluted EPS (ttm)

    -0.08

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    62.96M

  • Total Debt/Equity (mrq)

    669.89%

  • Levered Free Cash Flow (ttm)

    13.88M

Company Insights: BPMUF

People Also Watch